Drugs / IPH6501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06088654 | Mar 2024 → Feb 2026 | B-cell non-Hodgkin lymphoma | Innate Pharma | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-06-13 | Innate Pharma | Results Innate Pharma highlights preclinical antitumor activity of IPH6501 in diffuse large B-cell lymphoma and follicular lymphoma at the 2025 European Hematology Association (EHA) congress innate-pharma.com ↗
In preclinical in vitro models, IPH6501 demonstrated potent NK cell proliferation and tumor cell killing activity in DLBCL and FL patient samples, supporting its therapeutic potential in these indications. |
| 2024-11-19 | Innate Pharma | Results Innate Pharma announces publication in Science Immunology highlighting innovative next-generation ANKET® IPH6501 innate-pharma.com ↗
The data published shows that IPH6501, also called CD20-NKCE-IL2v in the publication, boosts NK cell proliferation and cytotoxicity, showing activity against a range of B-NHL cell lines, including those with low CD20 density. |
| 2023-06-10 | Innate Pharma | Results Innate Pharma highlights proprietary tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 congress innate-pharma.com ↗
A surrogate of IPH6501 mediated a potent anti-tumor activity in vivo in CD20+ tumor models in mice. |
All press releases naming this drug 6 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPH6501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06088654 ↗ |